Ivosidenib for advanced IDH1-mutant cholangiocarcinoma

被引：0
|
作者：
Gervaso, Lorenzo [1 ]
Pellicori, Stefania [1 ]
Fazio, Nicola [1 ]
机构：
[1] European Inst Oncol, Div Gastrointestinal Med Oncol & Neuroendocrine T, I-20141 Milan, Italy
来源：
LANCET ONCOLOGY | 2020年 / 21卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E370 / E370
页数：1
相关论文
共 50 条
  • [1] Ivosidenib for IDH1-mutant cholangiocarcinoma
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2020, 5 (07): : 647 - 647
  • [2] An evaluation of ivosidenib for the treatment of IDH1-mutant cholangiocarcinoma
    Tella, Sri Harsha
    Mahipal, Amit
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (17) : 1879 - 1885
  • [3] Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study
    Lowery, Maeve A.
    Burris, Howard A., III
    Janku, Filip
    Shroff, Rachna T.
    Cleary, James M.
    Azad, Nilofer S.
    Goyal, Lipika
    Maher, Elizabeth A.
    Gore, Lia
    Hollebecque, Antoine
    Beeram, Muralidhar
    Trent, Jonathan C.
    Jiang, Liewen
    Fan, Bin
    Aguado-Fraile, Elia
    Choe, Sung
    Bin Wu
    Gliser, Camelia
    Agresta, Samuel, V
    Pandya, Shuchi S.
    Zhu, Andrew X.
    Abou-Alfa, Ghassan K.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2019, 4 (09): : 711 - 720
  • [4] Ivosidenib effective in IDH1-mutant AML
    Peter Sidaway
    Nature Reviews Clinical Oncology, 2018, 15 : 472 - 472
  • [5] Clinical Utility of Ivosidenib in the Treatment of IDH1-Mutant Cholangiocarcinoma: Evidence To Date
    Uson Junior, Pedro Luiz Serrano
    Borad, Mitesh J.
    CANCER MANAGEMENT AND RESEARCH, 2023, 15 : 1025 - 1031
  • [6] Ivosidenib effective in IDH1-mutant AML
    Sidaway, Peter
    NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (08) : 472 - 472
  • [7] Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study
    Fan, Bin
    Abou-Alfa, Ghassan K.
    Zhu, Andrew X.
    Pandya, Shuchi S.
    Jia, Hongxia
    Yin, Feng
    Gliser, Camelia
    Hua, Zhaowei
    Hossain, Mohammad
    Yang, Hua
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 93 (05) : 471 - 479
  • [8] Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study
    Bin Fan
    Ghassan K. Abou-Alfa
    Andrew X. Zhu
    Shuchi S. Pandya
    Hongxia Jia
    Feng Yin
    Camelia Gliser
    Zhaowei Hua
    Mohammad Hossain
    Hua Yang
    Cancer Chemotherapy and Pharmacology, 2024, 93 : 471 - 479
  • [9] Cost-effectiveness of ivosidenib versus chemotherapy for previously treated IDH1-mutant advanced intrahepatic cholangiocarcinoma in Taiwan
    Chen, Kuei-An
    Huang, Wei-Ming
    Chen, Eric Yi-Ting
    Ho, Pei-Kuan
    Chueh, Chen-Han
    Wen, Yu-Wen
    Chen, Ming-Huang
    Chiang, Nai-Jung
    Tsai, Yi-Wen
    BMC CANCER, 2024, 24 (01)
  • [10] COST-EFFECTIVENESS ANALYSIS OF IVOSIDENIB VERSUS CHEMOTHERAPY FOR PREVIOUSLY TREATED IDH1-MUTANT ADVANCED INTRAHEPATIC CHOLANGIOCARCINOMA IN TAIWAN
    Chen, K. A.
    Huang, W. M.
    Chen, E. Y. T.
    Ho, P. K.
    Chiang, N. J.
    Tsai, Y. W.
    VALUE IN HEALTH, 2023, 26 (06) : S1 - S2
12345